Accurate and fast delivery of key events and news of growing Genexine
Genexine, COVID-19 preventive vaccine, GX-19, clinical 1/2 phase approval
- The first domestic pharmaceutical company entered the clinical trial of COVID-19 in Korea
On March 13th, Genexine started the development of GX-19 by forming the COVID-19 DNA vaccine development consortium (Genexin, Binex, International Vaccine Institute, GeNBio, KAIST, and POSTECH). As a result of the close collaboration of the consortium members and the rapid evaluation of the Ministry of Food and Drug Safety, the clinical trial was approved within 3 months of departure.
The phase 1 of clinical trials will be completed within 3 months, and the phase 2 phase of clinical trials, will be expanded to multinational clinical trials, including countries where the spread of COVID-19 is severe in the second half of this year. Young Chul Sung, CEO, said, "We are working with several domestic and foreign partners including Binex to secure vaccine supply, and we will accelerate our preparations to supply sufficient amounts not only in Korea but also in countries with insufficient vaccines."